BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37743730)

  • 1. Incidence, risk factors, and management of alpelisib-associated hyperglycemia in metastatic breast cancer.
    Shen S; Chen Y; Carpio A; Chang C; Iyengar NM
    Cancer; 2023 Dec; 129(24):3854-3861. PubMed ID: 37743730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
    Rugo HS; André F; Yamashita T; Cerda H; Toledano I; Stemmer SM; Jurado JC; Juric D; Mayer I; Ciruelos EM; Iwata H; Conte P; Campone M; Wilke C; Mills D; Lteif A; Miller M; Gaudenzi F; Loibl S
    Ann Oncol; 2020 Aug; 31(8):1001-1010. PubMed ID: 32416251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting Hyperglycemia Among Patients Receiving Alpelisib Plus Fulvestrant for Metastatic Breast Cancer.
    Ge X; Behrendt CE; Yost SE; Patel N; Samoa R; Stewart D; Sedrak M; Lavasani S; Waisman J; Yuan Y; Mortimer J
    Oncologist; 2023 Jul; 28(7):e488-e492. PubMed ID: 36943382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer.
    Burnette SE; Poehlein E; Lee HJ; Force J; Westbrook K; Moore HN
    Breast Cancer Res Treat; 2023 Jan; 197(2):369-376. PubMed ID: 36409396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
    Vernieri C; Corti F; Nichetti F; Ligorio F; Manglaviti S; Zattarin E; Rea CG; Capri G; Bianchi GV; de Braud F
    Breast Cancer Res; 2020 Apr; 22(1):33. PubMed ID: 32252811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpelisib for
    André F; Ciruelos E; Rubovszky G; Campone M; Loibl S; Rugo HS; Iwata H; Conte P; Mayer IA; Kaufman B; Yamashita T; Lu YS; Inoue K; Takahashi M; Pápai Z; Longin AS; Mills D; Wilke C; Hirawat S; Juric D;
    N Engl J Med; 2019 May; 380(20):1929-1940. PubMed ID: 31091374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer.
    Rodón J; Demanse D; Rugo HS; Burris HA; Simó R; Farooki A; Wellons MF; André F; Hu H; Vuina D; Quadt C; Juric D
    Breast Cancer Res; 2024 Mar; 26(1):36. PubMed ID: 38439079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
    Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS
    JAMA Oncol; 2019 Feb; 5(2):e184475. PubMed ID: 30543347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
    Turner S; Chia S; Kanakamedala H; Hsu WC; Park J; Chandiwana D; Ridolfi A; Yu CL; Zarate JP; Rugo HS
    Oncologist; 2021 Jul; 26(7):e1133-e1142. PubMed ID: 33909934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.
    Mayer IA; Abramson VG; Formisano L; Balko JM; Estrada MV; Sanders ME; Juric D; Solit D; Berger MF; Won HH; Li Y; Cantley LC; Winer E; Arteaga CL
    Clin Cancer Res; 2017 Jan; 23(1):26-34. PubMed ID: 27126994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).
    Mayer IA; Prat A; Egle D; Blau S; Fidalgo JAP; Gnant M; Fasching PA; Colleoni M; Wolff AC; Winer EP; Singer CF; Hurvitz S; Estévez LG; van Dam PA; Kümmel S; Mundhenke C; Holmes F; Babbar N; Charbonnier L; Diaz-Padilla I; Vogl FD; Sellami D; Arteaga CL
    Clin Cancer Res; 2019 May; 25(10):2975-2987. PubMed ID: 30723140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancer.
    Cheung YM; Cromwell GE; Tolaney SM; Min L; McDonnell ME
    Breast Cancer Res Treat; 2022 Apr; 192(2):303-311. PubMed ID: 35000092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with
    Jhaveri K; Drago JZ; Shah PD; Wang R; Pareja F; Ratzon F; Iasonos A; Patil S; Rosen N; Fornier MN; Sklarin NT; Chandarlapaty S; Modi S
    Clin Cancer Res; 2021 Jul; 27(14):3867-3875. PubMed ID: 33947692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating Alpelisib-Induced Hyperglycemia with Very Low Carbohydrate Diets and Sodium-Glucose Co-Transporter 2 Inhibitors: A Case Series.
    Blow T; Hyde PN; Falcone JN; Neinstein A; Vasan N; Chitkara R; Hurd MA; Sardesai S; Lustberg MB; Flory JH; Volek JS; Goncalves MD
    Integr Cancer Ther; 2021; 20():15347354211032283. PubMed ID: 34259084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S.U.G.A.R: A Case to Outline Tactics for the Prevention of Alpelisib-Induced Hyperglycemia.
    Thomas K; Germain M; Loch MM
    J Investig Med High Impact Case Rep; 2022; 10():23247096221105249. PubMed ID: 35712858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+
    Pérez-Fidalgo JA; Criscitiello C; Carrasco E; Regan MM; Di Leo A; Ribi K; Adam V; Bedard PL
    Future Oncol; 2022 Jun; 18(19):2339-2349. PubMed ID: 35465733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
    André F; Ciruelos EM; Juric D; Loibl S; Campone M; Mayer IA; Rubovszky G; Yamashita T; Kaufman B; Lu YS; Inoue K; Pápai Z; Takahashi M; Ghaznawi F; Mills D; Kaper M; Miller M; Conte PF; Iwata H; Rugo HS
    Ann Oncol; 2021 Feb; 32(2):208-217. PubMed ID: 33246021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of alpelisib in breast cancer: A real-world analysis.
    Miller J; Armgardt E; Svoboda A
    J Oncol Pharm Pract; 2022 Jul; 28(5):1152-1156. PubMed ID: 35450470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-Reported Outcomes in Patients With
    Ciruelos EM; Rugo HS; Mayer IA; Levy C; Forget F; Delgado Mingorance JI; Safra T; Masuda N; Park YH; Juric D; Conte P; Campone M; Loibl S; Iwata H; Zhou X; Park J; Ridolfi A; Lorenzo I; André F
    J Clin Oncol; 2021 Jun; 39(18):2005-2015. PubMed ID: 33780274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.